24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500

Medical Disorders
Resources
Basic InformationLookupsLatest News
Most Cyclists Suffering Head Injuries Not Wearing Helmets: StudyLinks Between Smog, 2nd Pregnancies and Preterm BirthHeartburn Drug Zantac May Contain Small Amounts of Known Carcinogen, FDA SaysCDC Revises Number of Vaping-Linked Lung Illnesses to 380 in 36 StatesKidney Transplants Safe When Donors Had Hepatitis CLung Cancer Screening Can Detect Other Smoking IllsIs Your State One of the 'Most Obese' in America?How to Keep Your Bones Strong and Prevent FracturesHeart Attack Can Be More Lethal If Symptoms Are More GradualHealth Tip: Understanding MononucleosisNew Strain of Strep Causing Cases of Scarlet FeverHow to Fight Hidden Causes of InflammationFDA Approves First Treatment for ILD With Systemic Sclerosis, SclerodermaOccasional Naps Do a Heart Good, Swiss Study FindsA 'Supercool' Breakthrough for Patients Awaiting Liver TransplantTreatment for Very-Preterm Infants May Lead to Antibiotic ResistanceWhy Weight Gain Often Comes With AgeNew Prosthetic Leg Can Feel Touch, Reduce 'Phantom Limb' PainThe Alexander Technique: What Could It Do for You?Drink Coffee, Avoid Gallstones?Dark Skin No Protection Against Sun's Harmful RaysSome People Vaccinated Against Mumps May Not Be Protected: StudyDiabetes Control Has Stalled Across U.S.Vaping-Linked Lung Illnesses Double, Vitamin E Acetate Leading Suspect'First Responders' on 9/11 Face Lingering Heart Woes, Study FindsHealth Officials Close in on Culprit in Vaping Lung Injury CasesGoing Vegetarian Good for Your Heart, But May Up Stroke RiskEven Small Improvements in Cholesterol, Blood Pressure Help Prevent Heart AttackHealth Tip: Signs of GallstonesHigh Post-Hospital Death Rate Trails Ebola SurvivorsClues to Why Epileptic Seizures Can Halt BreathingWhat Works Best Against Varicose Veins?Poor Circulation in Legs? Statin Meds Can Keep You Living LongerHurricane Dorian Can Wreak Havoc on Heart HealthMore CT, MRI Scans Being Used, Despite Calls to Cut BackDrop the Pop: Soda Tied to Higher Risk of Early DeathCould You Be Having a Heart Attack?Body's Natural Chemicals May Help Protect 9/11 Responders' Health: StudyObese Teen Boys More Prone to Heart Attacks in Middle AgeWeight-Loss Surgery Drops Heart Disease, Death Risk for DiabeticsHealth Tip: Managing a Poison Ivy RashFor Men, Living Alone May Mean Poorer Control of Blood-Thinning MedsLifestyle May Matter More Than Your Genes in Early Heart DiseaseAfter Heart Attack, Stenting More Than the Blocked Artery May Be BestLong-Term 'Couch Potatoes' May Face Double the Odds for Early DeathHow Heart Health Factors May Affect Your Parkinson's RiskDonor Organs Often There for Patients in Need, But Doctors Say NoAs Lung Injury Cases Rise, CDC Says 'Don't Vape'Health Tip: Preventing Kidney StonesE-Scooters Plus Drinking: A Fast-Pass to the ER?
Questions and AnswersLinks
Related Topics

Diabetes

FDA Approves First Treatment for ILD With Systemic Sclerosis, Scleroderma


HealthDay News
Updated: Sep 9th 2019

new article illustration

MONDAY, Sept. 9, 2019 (HealthDay News) -- The U.S. Food and Drug Administration granted the first approval for a drug to slow the decline of pulmonary function in interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD), the agency announced Friday.

Ofev (nintedanib) capsules were approved in 2014 to treat adults with idiopathic pulmonary fibrosis and are now approved for patients with SSc-ILD. The recommended dosage is 150 mg twice daily 12 hours apart.

Approval of Ofev was based on data from SENSCIS, a phase 3 randomized, double-blind, placebo-controlled trial of 576 patients (20 to 79 years old) with SSc-ILD. Patients received treatment for at least 52 weeks and up to 100 weeks. During 52 weeks, patients receiving Ofev had a 44 percent slower loss in pulmonary function (41 mL/year) as measured by forced vital capacity compared with patients who received placebo. The most frequently reported serious adverse event was pneumonia, which was reported in 2.8 and 0.3 percent of patients who received Ofev and placebo, respectively. Thirty-four percent of patients who received Ofev experienced adverse reactions that led to permanent dose reductions, compared with 4 percent of patients who received placebo. The most frequently reported adverse reaction leading to permanent dose reduction with Ofev was diarrhea.

The drug's prescribing information includes warnings for patients with moderate or severe hepatic impairment, elevated liver enzymes and drug-induced liver injury, and gastrointestinal disorders. The FDA notes that Ofev can also cause embryo-fetal toxicity resulting in fetal harm, arterial thromboembolic events, bleeding, and gastrointestinal perforation. Patients taking P-gp and CYP3A4 inhibitors should be closely monitored for tolerability of Ofev, as these inhibitors can increase nintedanib exposure. Commonly reported side effects with Ofev include diarrhea, nausea, abdominal pain, vomiting, liver enzyme elevation, decreased appetite, headache, weight loss, and hypertension.

Approval of Ofev for patients with SSc-ILD was granted to Boehringer Ingelheim Pharmaceuticals.

More Information